Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 12/20 | 0.64 |
| ▸ | CYP11B2 | P19099 | 12/20 | 0.64 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6409767 | 0.90 | CYP11B1 (0.64) | CYP11B1CYP11B2CYP19A1CACNA1H | |
| SCHEMBL7187767 | 0.80 | CYP11B1 (0.60) | CYP11B1CYP11B2CYP19A1CACNA1H | |
| SCHEMBL7660878 | 0.79 | CYP11B1 (0.57) | CYP11B1CYP11B2 | |
| SCHEMBL1064258 | 0.79 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL8139285 | 0.77 | CYP11B1 (0.71) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL765399 | 0.77 | CYP11B1 (0.67) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL7571091 | 0.76 | CYP11B1 (0.56) | CYP11B1CYP11B2 | |
| SCHEMBL1758083 | 0.75 | CYP11B1 (0.68) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL7983220 | 0.73 | CYP11B1 (0.62) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL8143815 | 0.73 | CYP11B1 (0.62) | CYP11B1CYP11B2FSCN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114350-A1 | INHIBITORS OF PRENYLTRANSFERASES AS ANTIFUNGAL AGENTS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2025-04-10 | — | — | US | disclosed |
| EP-1090012-A4 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2005-04-06 | — | — | EP | disclosed |
| US-6562823-B1 | Inhibition of farnesyl-protein transferase has been shown to block the growth of Ras-transformed cells in soft agar | MERCK & CO., INC. | 2003-05-13 | — | — | US | disclosed |
| EP-1090012-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000001702-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114350-A1 | INHIBITORS OF PRENYLTRANSFERASES AS ANTIFUNGAL AGENTS | FNTA, FNTB, FDPS | CYP11B1 3101/4885CYP11B2 3669/4885DPP4 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.